SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76923.00
87.22 (0.11%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	Glenmark Pharmaceuticals Ltd.	Q V+ PT	61,928 Mid Cap	2,199.25 (0.22%)	45.47	5.89	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	Unichem Laboratories Ltd.	Q V PT	3,826 Small Cap	538.20 (-0.97%)	24.07	1.46	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	43,202 Mid Cap	2,574.05 (0.94%)	41.7	18.92	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Alkem Laboratories Ltd.	Q V+ PT	67,124 Mid Cap	5,630.80 (0.30%)	30.72	4.8	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Aarti Drugs Ltd.	Q V PT	3,752 Small Cap	409.40 (-0.40%)	19.25	2.42	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Bajaj Healthcare Ltd.	Q V PT	1,078 Small Cap	319.95 (-0.05%)	46.8	1.97	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,922 Small Cap	184 (-1.26%)	29.98	0.44	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,009 Small Cap	821.70 (0.89%)	23.73	2.82	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Indoco Remedies Ltd.	Q V+ PT	2,287 Small Cap	244.10 (-1.47%)	N/A	2.08	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	Hester Biosciences Ltd.	Q V PT	2,151 Small Cap	2,540 (0.45%)	41.29	5.58	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Laurus Labs Ltd.	Q V+ PT	92,623 Mid Cap	1,745.85 (1.84%)	84.7	16.43	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	Shilpa Medicare Ltd.	Q V+ PT	12,144 Small Cap	605 (-2.56%)	49.91	4.69	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Ipca Laboratories Ltd.	Q V+ PT	45,090 Mid Cap	1,768 (-0.52%)	39.81	5.65	7.35	1.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	Cohance Lifesciences Ltd.	Q V+ PT	16,444 Small Cap	429.15 (-0.15%)	91.75	4.2	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Cipla Ltd.	Q V PT	1,13,894 Large Cap	1,434.80 (1.77%)	33.79	3.24	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Kopran Ltd.	Q V PT	975 Small Cap	198.50 (-1.68%)	32.07	2.18	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Divis Laboratories Ltd.	Q V+ PT	1,96,881 Large Cap	7,455.70 (0.53%)	76.67	11.75	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	Alivus Life Sciences Ltd.	Q V PT	13,876 Small Cap	1,120.45 (-0.89%)	24.58	4.16	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Metropolis Healthcare Ltd.	Q V PT	11,981 Small Cap	590.30 (2.17%)	63.05	7.92	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	FDC Ltd.	Q V PT	6,794 Small Cap	414.20 (-0.74%)	23.76	2.73	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Gland Pharma Ltd.	Q V PT	40,049 Small Cap	2,458 (1.24%)	30.82	3.7	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Bliss GVS Pharma Ltd.	Q V+ PT	4,898 Small Cap	450.60 (-2.26%)	50.56	4.28	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Syngene International Ltd.	Q V+ PT	16,710 Small Cap	408.85 (-1.23%)	54.8	3.58	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	Advanced Enzyme Technologies Ltd.	Q V PT	3,555 Small Cap	315 (-0.77%)	26.97	5.07	9.82	13.51	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Suraksha Diagnostic Ltd.	Q V PT	1,300 Small Cap	249 (-0.28%)	40.4	5.31	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Abbott India Ltd.	Q V PT	59,102 Mid Cap	27,892.65 (0.28%)	38.08	12.45	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	10,638 Small Cap	664.25 (-1.72%)	95.29	4.38	10.00	11.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	Piramal Pharma Ltd.	Q V PT	25,569 Small Cap	188.40 (-1.90%)	36.53	3.17	10.23	-6.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Wanbury Ltd.	Q V+ PT	1,157 Small Cap	318.55 (-3.82%)	17.5	8.01	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,382 Small Cap	368.65 (-0.08%)	18.42	4.57	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.75	3.26%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	590.30	2.17%
Laurus Labs	1,745.85	1.84%
Cipla	1,434.80	1.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,121.05	-7.35%
Senores Pharmaceutic	1,317.55	-6.66%
Suven Life Sciences	297.85	-4.44%
Wanbury	318.55	-3.82%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Cipla gets USFDA’s approval for Generic Advair Diskus

The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and COPD

Jul, 2026

Ipca Laboratories informs about board meeting

Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Thursday, 13th August, 2026, to consider and take on record the standalone and consolidated unaudited financial results of the Company for the 1st quarter ended 30th June, 2026 of the financial year 2026-27. Further, with reference to the above meeting of the Board of Directors, it has already informed vide its letter dated 22nd June, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st July, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results for the 1st quarter ended 30th June, 2026 i.e., till 15th August, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Gland Pharma informs about board meeting

Gland Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026, inter alia, to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

Jul, 2026

Divi's Laboratories informs about earnings call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi's Laboratories has informed that it enclosed the schedule of earnings conference call for the quarter ended June 30, 2026, to be held on August 01, 2026.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Jubilant Pharmova Ltd.	15,582 Crore
2	Suven Life Sciences Ltd.	8,807 Crore
3	Aster DM Quality Care Ltd.	70,000 Crore
4	Panacea Biotec Ltd.	2,654 Crore
5	Sanofi India Ltd.	7,760 Crore
6	Nectar Lifesciences Ltd.	202 Crore
7	Novartis India Ltd.	4,023 Crore
8	Aurobindo Pharma Ltd.	89,115 Crore
9	Apollo Hospitals Enterprise Ltd.	1,27,149 Crore
10	Solara Active Pharma Sciences Ltd.	2,439 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,631	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,553	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,587	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,146	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,73,509	41.25	5.67	23.65	14.41

You have 6 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Cipla gets USFDA’s approval for Generic Advair Diskus

Ipca Laboratories informs about board meeting

Gland Pharma informs about board meeting

Laurus Labs - Quaterly Results

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Divi's Laboratories informs about earnings call

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.